Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Biomarker in Tissue Samples From Patients With Ewing Sarcoma

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT01365949
First received: June 1, 2011
Last updated: July 7, 2016
Last verified: July 2016

June 1, 2011
July 7, 2016
May 2011
July 2016   (final data collection date for primary outcome measure)
Frequency of INI1 protein loss in Ewing Sarcoma [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01365949 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biomarker in Tissue Samples From Patients With Ewing Sarcoma
INI-1 Deletions in Ewing Sarcoma

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in tissue samples from patients with Ewing sarcoma.

OBJECTIVES:

  • To determine the frequency of INI-1 protein loss in Ewing Sarcoma.

OUTLINE: Previously collected tissue samples are analyzed for INI-1 protein loss by IHC and tissue microarray.

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:
Tissue
Non-Probability Sample
Diagnosis of Ewing sarcoma.
Sarcoma
  • Genetic: microarray analysis
  • Genetic: protein analysis
  • Other: immunohistochemistry staining method
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
Not Provided
July 2016   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of Ewing sarcoma
  • Prepared tissue microarray with Ewing sarcoma samples available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
up to 120 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01365949
AEWS11B1, COG-AEWS11B1, NCI-2011-02857, AEWS11B1
No
Not Provided
Not Provided
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Joshua D. Schiffman, MD University of Utah
Children's Oncology Group
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP